Barclays Analysts Give Merck KGaA (FRA:MRK) a €82.00 Price Target

Barclays set a €82.00 ($95.35) price objective on Merck KGaA (FRA:MRK) in a research note released on Monday, April 8th, Borsen Zeitung reports. The firm currently has a sell rating on the healthcare company’s stock.

Other equities research analysts have also recently issued research reports about the company. DZ Bank restated a neutral rating on shares of Merck KGaA in a research note on Tuesday, April 2nd. Kepler Capital Markets set a €110.00 ($127.91) price target on Merck KGaA and gave the stock a buy rating in a research note on Monday, April 1st. Deutsche Bank set a €93.00 ($108.14) price target on Merck KGaA and gave the stock a neutral rating in a research note on Monday, December 10th. Warburg Research set a €103.00 ($119.77) price target on Merck KGaA and gave the stock a neutral rating in a research note on Thursday, February 28th. Finally, Societe Generale set a €105.00 ($122.09) price objective on Merck KGaA and gave the stock a neutral rating in a report on Wednesday, March 27th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and five have given a buy rating to the company. Merck KGaA currently has a consensus rating of Hold and an average price target of €100.95 ($117.38).

Shares of Merck KGaA stock traded up €1.02 ($1.19) during trading hours on Monday, hitting €95.88 ($111.49). 420,801 shares of the company were exchanged. Merck KGaA has a 1 year low of €76.60 ($89.07) and a 1 year high of €115.00 ($133.72).

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Featured Article: Calculating net profit and net profit margin ratio

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.